N-Isopentyl-naphthalsaeureimid | 39061-44-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: N-Isopentyl-naphthalsaeureimid
• 英文别名: 2-(3-methyl-butyl)-benzo[de]isoquinoline-1,3-dione；2-(3-Methylbutyl)benzo[de]isoquinoline-1,3-dione
• CAS: 39061-44-4
• 化学式: C₁₇H₁₇NO₂
• 分子量: 267.327
• InChiKey: SGFGPWVQVREVEW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  37.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  萘亚胺 、 1-溴代异戊烷 在 sodium hydroxide 、 [R₃NC₅H₁₁]NO₃ 作用下， 以 甲苯 为溶剂， 反应 3.5h， 以90%的产率得到N-Isopentyl-naphthalsaeureimid
  参考文献：
  名称：

  Anikin; Krasnova; Kupriyan, Russian Journal of Applied Chemistry, 2000, vol. 73, # 3, p. 486 - 489

  摘要：

  DOI：

文献信息

• Target Enzyme‐Activated Two‐Photon Fluorescent Probes: A Case Study of CYP3A4 Using a Two‐Dimensional Design Strategy
  作者：Jing Ning、Wei Wang、Guangbo Ge、Peng Chu、Feida Long、Yongliang Yang、Yulin Peng、Lei Feng、Xiaochi Ma、Tony D. James

  DOI：10.1002/anie.201903683

  日期：2019.7.15

  development of fluorescent probes for monitoring target enzymes is still a great challenge owing to the lack of efficient ways to optimize a specific fluorophore. Herein, a practical two‐dimensional strategy was designed for the development of an isoform‐specific probe for CYP3A4, a key cytochrome P450 isoform responsible for the oxidation of most clinical drugs. In first dimension of the design strategy

  由于缺乏优化特定荧光团的有效方法，用于监测目标酶的荧光探针的快速开发仍然是一个巨大的挑战。本文设计了一种实用的二维策略，用于开发针对CYP3A4的同工型特异性探针，CYP3A4是负责大多数临床药物氧化的关键细胞色素P450同工型。在设计策略的第一个维度中，使用基于集合的虚拟筛选有效地选择了CYP3A4的潜在双光子荧光底物（NN）。在第二维中，将各种取代基引入到NN中，以优化异构体的选择性和反应性。最后，具有理想的选择性和灵敏度，NEN已成功应用于活细胞和斑马鱼中CYP3A4的实时检测。这些发现表明我们的策略对于开发针对靶酶的同工型特异性探针是可行的。
• Compositions and methods for modulating interaction between polypeptides
  申请人：Kazantsev G. Aleksey

  公开号：US20050239833A1

  公开（公告）日：2005-10-27

  The present invention is based, in part, on assays we conducted that revealed compounds that may be used to treat or prevent diseases characterized by an abnormal or undesirable association of one protein with another.

  本发明部分基于我们所进行的检测，这些检测揭示了可用于治疗或预防以一种蛋白质与另一种蛋白质的异常或不良结合为特征的疾病的化合物。
• ANTIMICROBIAL 2-DEOXYSTREPTAMINE COMPOUNDS
  申请人：Hanessian Stephen

  公开号：US20080045468A1

  公开（公告）日：2008-02-21

  The present invention is directed to analogs of paromomycin having a variety of chemical functional groups attached at the 2″-O-position as well as their preparation and use as prophylactic or therapeutics against microbial infection.
• ANTIBACTERIAL 4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS HAVING MULTIPLE SUBSTITUENTS
  申请人：Swayze Eric E.

  公开号：US20080293649A1

  公开（公告）日：2008-11-27

  The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection.
• COMPOSITIONS AND METHODS FOR MODULATING INTERACTION BETWEEN POLYPEPTIDES
  申请人：The General Hospital Corporation

  公开号：US20130203733A1

  公开（公告）日：2013-08-08

  The present invention is based, in part, on assays we conducted that revealed compounds that may be used to treat or prevent diseases characterized by an abnormal or undesirable association of one protein with another.